International Procurement of Treatment for People Suffering from Chronical Viral Hepatitis finalizedJun 1, 2016
26 May 2016, Kiev – The procurement process to supply medicines for children and adults with chronical viral hepatitis is now finalized as the United Nations Development Programme (UNDP) has signed contracts with 4 companies - GlaxoSmithKline Pharmaceuticals Ukraine, Ltd., Lumier Pharma Ltd, Macleods Pharmaceuticals Ltd., Valartin Pharma Ltd. Two more contracts with Delta Medical Promotions AG and Farmadis Ltd will be signed within coming days.
Lamivudine; Peginterferon alfa 2a; Peginterferon alfa-2b will be delivered in coming days; Ribavirin, Sofosbuvir, Tenofovir will be delivered within coming months, for a total amount of USD 5,283,014.98. Close to 90% of deliveries will be completed by the end of June 2016.
“According to WHO data there are more than 1,2 million people infected by Hepatitis C today in Ukraine. It is crucial for Ukraine to receive high quality medicines in time to save lives of those who are affected by the disease. We are proud that thanks to our competitive and transparent procedures, Ukraine patients will receive high quality medicines at the lowest international prices”, - said Janthomas Hiemstra, UNDP Country Director.
- UNDP-led procurement processes are part of an agreement signed in October 2015 upon MoH’s request to ensure the quality, timely delivery and optimal pricing of medicines to patients across Ukraine. This agreement is expected to run in parallel with a capacity building and transfer knowledge programme to ensure Ukrainian ownership of the medicine procurement process in the future, and its full management with transparency, accountability and integrity.
- The contracts have been awarded to the lowest priced bids per lot, if the company meets following selection criteria, including: valid registration in Ukraine at the time of supply, compliance with shelf life, packing and labelling requirements. The product(s) must be procured on the condition that they are either: a) Prequalified by WHO, and/or; b) Approved by a Stringent National Medicines Regulatory Authority (SRA) as defined by WHO, and/or; c) Recommended by the Expert Review Panel of the Global Fund, and/or; d) Manufactured at sites with a GMP certificate provided by WHO or PIC/S authorities and Registered in Ukraine and the supplier has successfully completed at least one supply contract for this product in Ukraine within the past three years (since December 2012). More detailed information about selection criteria here.
- As the development arm of the United Nations, UNDP supports strategic capacity development initiatives to promote inclusive growth and sustainable human development. Through partnerships with national, regional, and local governments, civil society, and the private sector, UNDP strives to support Ukraine in its efforts to eliminate poverty, develop people’s capacity, achieve equitable results, sustain the environment and advance democratic governance.
More information on the project and procurement processContact information
Contacts: Yevgeniy Zelenko, Yevgeniy.firstname.lastname@example.org; Tel.: +38 044 253-9363+38 044 253-9363 ext.141